Brad Rees: Chairman of the Board Mr Brad Rees is involved in a number of charitable, arts, education and medical research interests. He was previously a managing director and equity partner of the investment banking firm Goldman Sachs JB Were. Mr Rees was with the firm for 23 years, working in Melbourne, Sydney and London offices providing investment banking advice to major corporations and governments in Australia and overseas. He is a director of the Garvan Research Foundation Board and member of the Garvan's Investment committee.
Remy Robert: Director Dr Robert is a research fellow in the Department of Molecular Biology and Biochemistry (Monash University) and leads the efforts at Monash further devloping antibodies licensed from G2. Dr Robert is an expert in therapeutic antibody development and antibody engineering. In 2007 he was awarded the prestigious CSIRO OCE (Office of the Chief Executive) Postdoctoral Fellowship. Dr Robert’s goal is to move academic science into translation in the form of new antibody therapies using cutting-edge protein engineering techniques and human receptor knock-in mice.
Christina Hardy: Director Ms Christina Hardy is Director - Corporate, Legal and Partnerships at the Garvan Institute of Medical Research. She is a senior business executive with a successful track record in strategic business development, technology commercialisation and driving transformational change. Ms Hardy is a non-Executive Director of the Bionics Institute and of the Bario Pite Hosptial in Timor.
Andrew Adamovich: Director Mr Andrew Adamovich is a Founder and Director of Riverland Capital Limited, Director of Amara Enterprises Limited, Yuan Chuan
(Cayman) Limited, China Education Corporation, and ASX-listed Ambition Group
Limited. Previously Andrew was an Associate with the Zurich Centre Group
and a Director at Equity Partners Asia Limited. Mr. Adamovich has over ten
years experience in finance, focused on direct investment in Asia. Mr.
Adamovich has a Bachelor of Arts degree from the University of California,
Peter Whitfeld: Company Secretary & General Manager Dr Peter Whitfeld has over 25 years experience in biotechnology research, development and management. He is currently a Senoir Manager in the Partnerships Office at the Garvan Institute and also manages the C5aR program at G2 Therapies. Previously he lead the team responsible for humanising G2's therapeutic antibodies and was a senior staff member in the Immunology and Inflammation Research Program at the Garvan Institute. Prior to joining G2 and the Garvan, Dr Whitfeld held senior research and managerial positions at GroPep and Biotech Australia. He held post doctoral research positions at CSIRO, Fox Chase Cancer Center and Prince Henrys Institute for Medical Research after completing a PhD at the Australian National University, Research School of Biological Sciences.